AVBP - ArriVent BioPharma, Inc.
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law.
/PRNewswire/ -- Before the opening bell today, ArriVent BioPharma (NASDAQ: AVBP) shares were already down 56.7% in premarket trading after the Company
AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- A 56.7% premarket plunge hit AVBP shareholders on October 6, 2026, after ArriVent BioPharma (NASDAQ: AVBP) announced that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint.
ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data.
ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) reached a new 52-week low during trading on Tuesday. The company traded as low as $11.66 and last traded at $12.00, with a volume of 1687237 shares traded. The stock had previously closed at $28.46. Analysts Set New Price Targets A number of research firms have recently
NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review (BICR).
ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the
Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 39,180 shares of the company's stock, valued at approximately $1,361,000. Deutsche Bank AG owned 0.08% of ArriVent BioPharma at the end
The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming meaningful penetration across EGFR exon 20 insertion and PACC populations. Pipeline optionality is expanding, with ARR-217 entering Phase 1 and ARR-002 approaching first-patient dosing.
Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy
Dimensional Fund Advisors LP lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) by 758.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,525 shares of the company's stock after acquiring an additional 111,782 shares during the
NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent Company progress.
Affinity Asset Advisors LLC lifted its position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) by 16.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,000 shares of the company's stock after purchasing an additional 25,000 shares during the
Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulation rather than operational issues, enrollment challenges, or trial redesign. ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term funding risk while supporting late-stage development and commercialization efforts. Shanghai Allist continues to demonstrate strong commercial momentum in China, while ARR-002 adds a new potential growth driver.
NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.
NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.
Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.